Background {#Sec1}
==========

Type 2 diabetes mellitus is associated with an increased risk of dementia \[[@CR1], [@CR2]\] and more specifically, a two-fold increase in the risk of Alzheimer's disease \[[@CR3]\]. Many factors may contribute to this strong association, including increased stroke incidence, white matter microstructural changes, hyperinsulinaemia and metabolic syndrome, as well as the cross-association of mid-life obesity and type 2 diabetes \[[@CR4]\]. A diagnosis of diabetes in midlife increases the risk of both vascular cognitive impairment and Alzheimer's disease \[[@CR5]\].

Magnetic resonance imaging (MRI) markers of structural brain aging such as reduced total brain volume, cortical thickness, hippocampal volume, and increasing white matter hyperintensity load, are correlated with performance on neuropsychological tests and are powerful predictors of dementia \[[@CR6], [@CR7]\]. A strong association between midlife vascular risk factors and structural brain aging has been demonstrated \[[@CR8]\], although longitudinal brain volume changes have not been thoroughly examined in patients with type 2 diabetes. The PROSPER study findings suggested that elderly non-demented patients with type 2 diabetes had accelerated progression of brain atrophy compared to non-diabetic individuals and provided evidence for the hypothesis that diabetes exerts deleterious effects on neuronal integrity \[[@CR9]\].

There is little evidence that intensive glycaemic management as reflected by lower HbA~1c~ levels in type 2 diabetes is associated with reduced dementia risk \[[@CR10], [@CR11]\] or cognitive decline \[[@CR12]\]. The ACCORD-MIND study investigators \[[@CR10]\] found no evidence that an intensive glycaemic treatment strategy targeting HbA~1c~ to \<6% altered cognitive outcomes in patients with type 2 diabetes. However, the ACCORD study was halted due to higher mortality rates from cardiovascular events in the intensive arm \[[@CR13]\]. Subsequent follow-up of the ACCORD-MIND participants found an association between poor cognitive function and the risk of severe hypoglycaemic events \[[@CR14]\]. A further 80 months of follow-up in the ACCORDION MIND trial showed no long term benefits of intensive glycaemic control on cognition or brain MRI outcomes \[[@CR15]\]. It therefore remains unclear if tight glycaemic control as reflected by lower HbA~1c~ levels lead to lower risk of dementia and better biomarkers are needed for the prediction of cognitive decline to stratify the risk of dementia in type 2 diabetes.

Patients with type 2 diabetes have associated hypertension \[[@CR16]\], a high prevalence of previously unknown heart failure \[[@CR17]\] and left ventricular dysfunction \[[@CR17], [@CR18]\]. Left ventricular hypertrophy (LVH) is also highly prevalent in patients with type 2 diabetes \[[@CR18]\] and hypertension \[[@CR19]\] and is an established independent predictor of adverse cardiovascular outcomes, including stroke \[[@CR20]\] and heart failure \[[@CR21]\]. Patients with type 2 diabetes and co-morbid hypertension have increased left ventricular mass, more concentric left ventricular geometry, lower myocardial function, that is independent of age, sex, body size, arterial blood pressure and atherosclerosis, compared to hypertensive individuals without type 2 diabetes \[[@CR16]\]. Diabetes and hypertension predispose to the ischemic small vessel disease underlying lacunar infarction. Lacunar infarction can result in cognitive decline from selective damage to frontal-subcortical circuits subserving processing speed and executive function, and these deficits are often observed in type 2 diabetes \[[@CR22]\].

There is a strong association between cardiac disease and impairment across many cognitive domains, particularly in tests of executive function \[[@CR23]\]. Heart failure is strongly associated with cognitive impairment \[[@CR24]--[@CR26]\] and is an independent risk factor for the development of Alzheimer's disease and cerebrovascular disease \[[@CR16]\]. Carotid atherosclerosis is associated with cognitive impairment \[[@CR27]\], measures of structural brain aging \[[@CR8]\] and reductions in parietal gray matter \[[@CR8]\]. LVH is associated with progressive cognitive decline, independent of blood pressure and large artery stiffness \[[@CR28]\]. Left ventricular mass is associated with worse performance on tests of both visuospatial and verbal memory \[[@CR29]\], and there is a nonlinear association between left ventricular ejection fraction (EF) and measures of accelerated structural and cognitive brain aging \[[@CR30]\].

The D2 (diabetes and dementia) study {#Sec2}
------------------------------------

The diabetes and dementia study (D2) study is an observational study in which we will intensively study the cardiovascular status of patients with type 2 diabetes and investigate if LVH predicts cognitive function, or if specific cardiac indices predict cognitive decline and brain atrophy. We will recruit participants with type 2 diabetes and integrate transthoracic echocardiography, carotid imaging, brain imaging with MRI, circulating and genetic biomarkers, and neuropsychology tools, to establish the relationship between type 2 diabetes, brain atrophy, and cognitive decline in a cohort of 168 individuals with and without LVH. At baseline, all participants will have structural neuroimaging with MRI to assess global brain volume, regional cortical thickness and hippocampal volume, a 12 lead electrocardiogram (ECG), an echocardiogram to assess the absence or presence of LVH, a carotid ultrasound to assess vascular disease, 24-h ambulatory blood pressure and ECG, cognitive assessment, and apolipoprotein E (*APOE*) gene risk assessment. All of the aforementioned assessment tools will be repeated at the 24-month follow up period.

Methods {#Sec3}
=======

The D2 study has been approved by the Human Research Ethics Committee at Austin Health (HREC/15/Austin/490) and is registered at the Australian New Zealand Clinical Trials Registry (ACTRN12616000546459). Funding is provided through the National Health and Medical Research Council of Australia (APP1094974). Informed written consent is obtained from the participants prior to any data collection.

D2 Study design {#Sec4}
---------------

The D2 study is a single center, observational, longitudinal, case-control study. One hundred and sixty-eight adult patients, aged greater than 50 years with type 2 diabetes will be followed: 50% with LVH (case) and 50% without (control). Patients will be assessed at baseline (0 months) and will return for tests at the 24 month time-point. Based on recruitment in our other diabetes, cognitive and imaging trials, it is expected that 80--90 patients will be recruited annually for the first 2 years. Recruitment of new patients will be completed at the end of 2 years, allowing the next 2 years for follow-up.

Study hypotheses {#Sec5}
----------------

Patients with type 2 diabetes and LVH will exhibit greater brain atrophy as assessed by MRI structural changes than those without LVH.Brain atrophy as assessed by MRI structural changes will be associated with worse cognitive performance.Increased left ventricular mass with specific left ventricular geometric patterns will be associated with the most severe regional brain atrophy and cognitive decline.

Study aims {#Sec6}
----------

To establish whether diabetic patients with LVH have increased rates of brain atrophy and cognitive decline.To establish whether the specific LV geometric measures are associated with these brain volume changes.

Study outcome measures {#Sec7}
----------------------

Our primary endpoint is brain volume change at 2 years (hypothesis 1). Our co-primary outcome is the presence of cognitive decline at 2 years (hypothesis 2). We shall use advanced brain imaging to accurately measure brain volume and correlate this with cardiac echocardiography, carotid intima media thickness (CIMT), and 24 h blood pressure and ECG monitoring in 168 patients with type 2 diabetes, with longitudinal testing allowing measurement of change at 24 months. Concurrent neuropsychological testing will indicate whether the clinical profile of cognitive impairment and dementia aligns with measures of brain volume.

Eligibility criteria {#Sec8}
--------------------

Inclusion criteria are as follows: (1) aged over 50 years; (2) no prior neurological or psychiatric disease, including stroke; (3) ability to give informed consent and participate in cognitive testing. The study exclusion criteria are as follows: (1) known prior stroke, transient ischemic attack or dementia; (2) significant medical co-morbidities precluding participation in cognitive testing, or making survival for 24 months unlikely; (3) normal exclusion criteria for MRI; e.g., implanted metal, severe claustrophobia; (4) severe diabetic nephropathy: estimated glomerular filtration rate (eGFR \<30 mL/min/1.73 m^2^).

Study assessments {#Sec9}
-----------------

The schedule of assessments is provided in Table [1](#Tab1){ref-type="table"}. Testing will include the following: a pre-study screening questionnaire and MRI safety check to determine eligibility; demographic and medical history questionnaire; clinic measurement of height, weight, waist and hip; echocardiogram, ECG; CIMT; 24 h ambulatory blood pressure and ECG monitor; cognitive assessment; MRI scan; physical activity monitor; and a blood sample (to determine *APOE* genetic risk and analyses of genetic and plasma/serum biomarkers).Table 1Schedule of assessments at baseline (0 months) and 24 monthsAssessmentsBrief descriptionTime-point (months)024Pre-study screening questionnaire (to determine study eligibility)Study eligibility criteria✓MRI safety check questionnaireMRI eligibility✓✓Demographic and medical history questionnaireQuestionnaire completed with the study investigator✓✓Weight, height, waist and hip measurementClinical assessment✓✓Transthoracic echocardiogramAssess cardiac structure and function✓✓Blood samplePlasma electrolytes, glucose, HbA~1C~, lipids and urinary analyses. Blood collected for *APOE* genotyping and assessment of other genetic and circulating biomarkers.✓✓Carotid intimal medial thicknessB-mode ultrasound to assess left and right internal carotid arteries and the degree of stenosis✓✓24 h ambulatory blood pressure and ECG HolterSimultaneous measurement of blood pressure and ECG✓✓MRI scanning on a Siemens 3 T Skyra scanner using a 64 Channel receive only head coil.• High resolution isotropic T1 3D MPRAGE (structural scan)✓✓• High resolution isotropic T2 FLAIR 3D• High resolution isotropic T2 3D• Susceptibility-weighted image (SWI) for iron deposition• Diffusion-weighted imaging (DWI)• GRE field mapping• BOLD 7 min free run (resting state connectivity)Cognitive and mood evaluationValidated tools for assessing mood, global cognitive ability, attention, visuospatial ability, executive function, language, memory, processing speed✓✓Physical activity assessmentSenseWear Armband (BodyMedia FIT)✓✓

Details of questionnaire and measurements {#Sec10}
-----------------------------------------

### Pre-study screening and MRI safety check questionnaires {#Sec11}

A short questionnaire will be used to ask questions related to the study eligibility, which will be key to identifying patients that may be unsuitable for MRI testing. Those identified as unsuitable will be informed at this stage and no further measurements will be conducted. Eligible participants will complete a detailed MRI safety questionnaire with the investigator to obtain more specific information about their history of surgical procedures to determine whether they have implants that might not be suitable for a 3 T MRI scan. Participants will be excluded if they cannot have a research 3 T MRI scan (e.g., because they have a metal implant that has not been cleared for safety in a 3 T MRI scanner).

### Demographic and medical history questionnaire {#Sec12}

A questionnaire and medical record review will be conducted at the time of the echocardiogram and blood collection. The following information will be collected: age, sex, duration of diabetes, smoking history, alcohol consumption, current drug therapy and dose, socioeconomic status family history of cardiovascular disease, medical history including general health and co-morbidities (cardiac disease, hypertension, dyslipidaemia, the presence of micro-vascular disease (nephropathy, retinopathy, neuropathy) and other macro-vascular complications (peripheral vascular disease). The questionnaire will be cross-checked by medical record review at Austin Health, and from their clinical and specialist reports if recruited outside of Austin Health.

### Physical measurements {#Sec13}

Participants' height and weight (to determine body mass index (BMI) and body surface area) will be assessed. Weight will be measured to the nearest 0.1 kg on standing digital scales without shoes and light clothing. Height will be measured using a wall-mounted stadiometer to the nearest 0.1 cm. Waist and hip circumferences will be measured using a spring loaded tape. Waist circumference is measured at the mid-point between the lower costal margin and the iliac crest. Hip circumference is measured over the greater trochanters.

### Transthoracic echocardiography (TTE) {#Sec14}

TTE will be performed by a cardiologist using a commercially available portable ultrasound system (Vivid i, GE Healthcare). Standard parasternal and apical views will be used to assess left ventricular mass. Measurements are obtained according to the American Society of Echocardiography (ASE) recommendations \[[@CR31]\]. M-mode echo will be used to measure cardiac dimensions and wall thickness. Ejection fraction will be calculated using the modified Simpson's rule. Left ventricular mass will be indexed using the ASE corrected convention, by dividing left ventricular mass by height^2.7^. LVH will be defined as \>49 g/m^2.7^ for males and \>45 g/m^2.7^ for females. Relative wall thickness will be calculated, and left ventricular remodelling classified as normal, eccentric, or concentric remodelling and concentric LVH.

### Blood collection and measurements {#Sec15}

Fasting plasma electrolytes, glucose, HbA~1C~, lipids and urinary analyses will be obtained on all patients at baseline and at 24 months. The D2 study will collect additional plasma, serum and whole blood for genetic analyses. The exploration of novel circulating biomarkers and genetic determinations that lead to LVH and/or brain atrophy will be conducted within our laboratory. Whole blood will be collected and divided between lithium heparin and EDTA tubes for plasma and genetic samples and a plain tube for serum. Serum will be extracted and aliquoted for storage at -80 °C until assayed. For plasma, the sample tube will be stored on ice and centrifuged within 15 min to separate the plasma. The plasma will be aliquoted for storage at -80 °C until assayed. Whole blood will be collected in a potassium EDTA tube and immediately stored at -80 °C until DNA extraction. *APOE* genotyping will be performed in our laboratory. Genomic DNA will be extracted using the Qiagen DNA Maxi kit (Qiagen, Germany) and the *APOE* region of interest will be amplified with specific primers. The resulting DNA fragment will be sequenced in the forward and reverse direction on an ABI 3130-xl genetic analyser (Applied Biosystems, CA, USA). Participants will be informed of their *APOE* ε4 status by the Principle Investigator and those with *APOE* ε4 homozygosity will be offered counselling via the Neurogenetics Clinic at Austin Health.

### Carotid Doppler ultrasound {#Sec16}

CIMT measurements will be conducted in the Neurology diagnostics laboratory, Austin Health by a single technician. High-resolution B-mode ultrasound images will be obtained on both right and left internal carotid arteries. CIMT will be measured, and the degree of stenosis will also be classified into accepted clinical grades for incorporation into multivariate analyses: none, \<50%, 50--69%, 70--79%, 80--89%, 90--99% and occluded (NASCET criteria) \[[@CR32]\].

### Ambulatory blood pressure and ECG monitoring {#Sec17}

Each participant will have a combined Holter monitor simultaneously assessing ambulatory blood pressure and ECG data (CardXplore, Meditech, Hungary).

### MRI acquisition and processing {#Sec18}

Scans will be acquired for gray and white matter anatomical, structural and functional connectivity and iron estimation analyses. High resolution structural MRI of study subjects will be acquired using a 3 T Siemens Skyra MR scanner. The following sequences will be acquired: T1-weighted three-dimension (3D) magnetization-prepared rapid gradient-echo (MP-RAGE) for anatomical analyses; susceptibility-weighted image (SWI) for iron estimation and microhemorrhage imaging; fluid-attenuated inversion recovery (FLAIR) to assess chronic white matter ischemic changes and diffusion weighted imaging (DWI) to assess white matter structural integrity.

Regional cortical gray matter atrophy will be assessed using vertex-wise cortical thickness analysis. Cortical thickness will be mapped using the FreeSurfer software package for analysis of structural MRI data (<http://surfer.nmr.mgh.harvard.edu/fswiki>) \[[@CR33]\]. The automated cortical and subcortical parcellation routines also provided with FreeSurfer will be used to investigate regional volume changes. We will use processing streams developed specifically by our group for longitudinal studies \[[@CR34], [@CR35]\]. Hippocampal volume changes will be assessed using manual hippocampal segmentation. Iron deposition and cerebral microbleeds will be assessed with susceptibility-weighted image analyses. The MRI protocol is provided in the Additional file [1](#MOESM1){ref-type="media"}.

### Cognitive and mood assessment questionnaire and tests {#Sec19}

Participants will complete a neuropsychological assessment. The assessment will include several paper-and-pencil and computerized cognitive tasks and mood questionnaires. Six cognitive domains will be examined, including (i) attention, (ii) visuospatial ability, (iii) executive function, (iv) language, (v) memory, and (vi) processing speed. The tasks used to measure each cognitive domain are listed in Table [2](#Tab2){ref-type="table"}. This protocol has been modelled on that validated by the CANVAS study, a longitudinal study of patients after stroke \[[@CR36]\]. All tasks are designed for serial testing and are less affected by practice effects. Performance on individual cognitive tests will be standardised using established norms and domain scores will be calculated by averaging the standardised scores from each contributing test (e.g., Trail Making Test as a measure of attention). Assessment of mood will be completed using the seven-item Generalized Anxiety Disorder (GAD-7) questionnaire and the nine-item Patient Health Questionnaire (PHQ-9). These questionnaires are based on criteria for the diagnosis of generalised anxiety and depression (Diagnostic and Statistical Manual-Fourth Edition: DSM-V) \[[@CR37]\].Table 2Tasks used to measure each cognitive domainCognitive domainCognitive taskGlobal Cognitive AbilityMontreal Cognitive Assessment \[[@CR45]\]The Clinical Dementia Rating \[[@CR46]\]National Adult Reading Task \[[@CR47]\]AttentionTrail-Making Test \[[@CR48]\]Digit Span Task (WAIS-IV) \[[@CR49]\]Identification Task (Computerised CogState battery) \[[@CR50]\]One Back Task (Computerised) \[[@CR50]\] CogState battery)Visuospatial AbilityRey Complex Figure Test (Copy) \[[@CR51]\]Executive FunctionClock Drawing Task -- CLOX \[[@CR52]\]Controlled Oral Word Association Test \[[@CR53]\]Language30-item Boston Naming Test \[[@CR54]\]Verbal Fluency Test \[[@CR53]\]MemoryRey Auditory Verbal learning Task \[[@CR55]\]Rey Complex Figure Test (Recall) \[[@CR51]\]Processing SpeedDetection Task (Computerized CogState battery) \[[@CR50]\]Digit-Symbol Task (WAIS-IV) \[[@CR49]\]

### Physical activity monitoring {#Sec20}

The SenseWear Pro2 Armband (HealthWear BodyMedia, Pittsburgh, PA, USA) is a portable device which enables monitoring of energy expenditure and activity. The device uses a two-axis accelerometer, a heat flux sensor, a galvanic skin response sensor, a skin temperature sensor, and a near-body ambient temperature sensor to capture data and will be worn by each participant on the upper arm for 7 days. The data will be converted into Metabolic Equivalents minutes (METs\*minutes) and energy expenditure using an algorithm (Bodymedia, Sense Wear 6.1) \[[@CR38]\]. The SenseWear monitor has been validated for measuring energy expenditure in diabetes against double-labeled water \[[@CR39]\].

Sample size {#Sec21}
-----------

We aim to recruit 168 patients with type 2 diabetes. Patients will be divided based on the presence of LVH. Higher left ventricular mass and concentric geometric changes have been demonstrated in approximately 35--40% of patients with type 2 diabetes \[[@CR16], [@CR17]\]. Our data suggested more than 50% of participants will have LVH \[[@CR18]\]. We calculated our sample size in order to include sufficient participant numbers for both the primary endpoint comparison (brain volume) and for the primary outcome measure (presence of cognitive impairment). The primary endpoint requires a direct comparison of two groups: type 2 diabetes patients with LVH and those without. We based our effect size on published brain volume and cortical thickness estimates performed on healthy controls, cerebrovascular disease patients and Alzheimer's disease patients \[[@CR40]--[@CR42]\], and prior imaging of healthy controls and stroke patients performed by our group \[[@CR43]\]. We use an average brain volume change of \<0.5% per annum for controls, 1--2% for cerebrovascular disease, and 2--4% for dementia \[[@CR44]\].

We used a modified retrospective case-control method. All participants have the exposure (type 2 diabetes), which will naturally halve by the additional risk factor (LVH, expected prevalence around 50%), but only some of them will develop the primary outcome (cognitive decline). We used an ANCOVA method to estimate sample size for four samples (cognitively impaired LVH, non-cognitively impaired LVH, cognitively impaired non-LVH, non-cognitively impaired non-LVH) with repeated measures, including a correlation score between baseline and follow-up. Using alpha = 0.05 (two-sided), power = 0.8 and an estimated correlation of 0.1, we estimated that 140 (i.e., 35 in each of 4 groups) participants will be required. Given we expect around 20% attrition due to death or non-participation (unable to participate in testing due to new pacemaker/implanted metal/other medical issue, lost to contact, no longer interested), we have estimated a total recruitment number of 168. This model has used the conservative estimates from these results and assumes the following: that 30% of patients will be cognitively impaired at 2 years; a 1% total annual brain volume change for patients with type 2 diabetes; that 30% of patients will exhibit specific left ventricular geometric changes; and a low correlation between baseline and follow-up measures.

Statistical analysis {#Sec22}
--------------------

The analysis of this study will be performed in three parts as follows.***Hypothesis 1: comparing brain volumes between participants with and without LVH***. Independent samples t-tests will be used to determine differences between participants with and without LVH at each time-point. Repeated-measures t-tests will be used to determine the extent of brain volume loss across the two time-points. These results will be compared between groups. In the cortical thickness analyses, the large number of statistical inferences being carried out across the cortical sheet (approximately 160,000 vertices per hemisphere) requires adjustment of the statistical threshold. This is to control for the increased number of false positive findings using false discovery rate correction procedure widely used for cortical thickness analyses. In the volumetric analyses, total brain volume, regional white matter, cortical and subcortical volume changes will be modelled using a repeated measures design. Intracranial volume, which is determined partially by gender and race, is a known confounding factor that contributes to regional brain volumes. This will be controlled for in the statistical analysis of regional brain volume change. We have demonstrated this to be a reliable index of brain volume in previous studies \[[@CR43]\].***Hypothesis 2: correlating brain volume with cognitive performance.*** The initial regressive analysis will examine differences between cognitively impaired and normal participants at 2 years. We will correlate both global and regional measures of brain volume with the groups. Global brain and regional hippocampal volumes, and mean regional cortical thickness values for the stated regions of interest will be compared between two groups, in order to correlate LVH-associated brain volume changes with cognition. We will also perform a multivariate analysis across the cohort as a whole to investigate whether there is a dose-related association with any extent of cardiac impairment. Multivariate regression will be conducted to determine whether brain volume loss correlates with the presence or absence of cognitive impairment, adjusting for known important variables such as age, years of education, CIMT, atrial fibrillation, cholesterol and hypertension, as well as potentially relevant variables including *APOE* ε4 status, cardiac indices such as stroke volume, renal function and HbA~1c~ levels.***Hypothesis 3: comparing brain volume and cognitive performance in participants with increased left ventricular mass and specific left ventricular geometric patterns.*** Analysis will be similar to that for LVH, except that patients will be divided on the presence or absence of specific morphometric measures. That is, analyses will be performed at each time-point (cross-sectional), and also longitudinally, to investigate change across time. Repeated-measures t-tests will determine the extent of brain volume loss across the two time-points and compared between groups. Correlation with cognitive performance will be performed as above. Unadjusted differences for clinical variables between groups will be assessed by *t*-test. Difference in laboratory data and left ventricular systolic function will be adjusted for age and sex by use of ANCOVA. Differences in left ventricular structure and geometry will be adjusted for age, sex, BMI, and systolic blood pressure as their major established covariates with further adjustment for duration of hypertension. Fisher's Exact Test and odds ratios will be used to test differences for categorical variables. Logistic regression analysis will be used to derive odds ratios adjusted for covariates. Multiple regression analyses will be performed to assess relation of cognitive and brain volume measures to higher left ventricular mass independent of established covariates and duration of hypertension.

Discussion {#Sec23}
==========

The D2 study will aim to improve the understanding of two of the major causes of death, disability and reduced quality of life in our society: diabetes and dementia. In an ageing population, it is vitally important that we increase our knowledge of the relationships between cardiovascular disease and cognition. We have the means to identify a potentially treatable risk factor in the causation of cognitive impairment. The study will provide unique information on the relationship between LVH and dementia in type 2 diabetes, and whether cardiac structural and functional abnormalities contribute to increased brain atrophy and cognitive impairment. Brain volume changes may precede cognitive changes, providing a potential for early diagnosis and intervention. A large proportion of these patients may have associated or superadded Alzheimer's pathology. These patients provide a high risk cohort requiring urgent intervention to prevent increasing dependence and disability. The identification of people at risk of cognitive impairment and dementia will allow for both secondary prevention and early intervention. With the advent of aggressive risk management strategies for cardiovascular disease, identification of these patients will allow them to be treated early in their disease course, ideally before they develop cognitive decline.

Additional file {#Sec24}
===============

Additional file 1:D2 Study MRI: Data acquired on a Siemens 3 T Skyra scanner using a 64 Channel receive only head coil. (DOCX 12 kb)
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